The Saga of Recombinant Human Pentraxin-2 as a Potential Therapeutic Agent for Pulmonary Fibrosis
touchREVIEWS in Respiratory & Pulmonary Diseases · 2024
DOI: 10.17925/usprd.2024.9.1.4 ↗Kurz gefasst
Fachartikel in der Zeitschrift touchREVIEWS in Respiratory & Pulmonary Diseases, 2024. Verfasst von Keith C Meyer. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
erum amyloid P (SAP) is an endogenous protein of hepatic origin that is constitutively present in the peripheral circulation and a member of the pentraxin family of proteins.Preclinical studies in animal models suggested that SAP (pentraxin-2) could blunt or prevent tissue fibrosis, including bleomycin-induced pulmonary fibrosis.Recombinant human pentraxin-2 was termed PRM-151 when it entered clinical trials for patients with idiopathic pulmonary fibrosis (IPF) or myelofibrosis over a decade ago.Despite the potential promise of PRM-151 (now known as zinpentraxin alfa) as a therapeutic intervention to treat fibrotic diseases and its potential efficacy for patients with IPF as suggested by a phase II randomized clinical trial (RCT), interim analyses of the data from the phase III RCT (STARSCAPE) in patients with IPF showed a lack of efficacy.The purpose of this article is to review the properties of pentraxin-2 and the promising findings on PRM-151 as an anti-fibrotic drug in preclinical studies and early-phase RCTs that supported its advance to a phase III RCT.Pentraxin-2 is a member of the pentraxin family of proteins, which includes C-reactive protein (CRP), pentraxin-2 and pentraxin-3.[1][2][3] When initially discovered and characterized, pentraxin-2 was known as serum amyloid P (SAP) due to its isolation from amyloid deposits in humans; subsequently, SAP was found to be in the sera from circulating blood and, hence, its designation as SAP.[4][5][6] Subsequent research revealed multiple biological properties and functions of SAP (Table 1).
Zitieren
APA
Meyer, K. C. (2024). The Saga of Recombinant Human Pentraxin-2 as a Potential Therapeutic Agent for Pulmonary Fibrosis. touchREVIEWS in Respiratory & Pulmonary Diseases. https://doi.org/10.17925/usprd.2024.9.1.4
Vancouver
Meyer KC. The Saga of Recombinant Human Pentraxin-2 as a Potential Therapeutic Agent for Pulmonary Fibrosis. touchREVIEWS in Respiratory & Pulmonary Diseases. 2024. doi:10.17925/usprd.2024.9.1.4
BibTeX
@article{Meyer2024,
author = {Meyer, Keith C},
title = {The Saga of Recombinant Human Pentraxin-2 as a Potential Therapeutic Agent for Pulmonary Fibrosis},
journal = {touchREVIEWS in Respiratory & Pulmonary Diseases},
year = {2024},
doi = {10.17925/usprd.2024.9.1.4}
}
EUVIMED